Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Overview
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Companies Involved in Therapeutics Development
Addex Therapeutics Ltd
Allos Pharma Inc
Allyx Therapeutics Inc
Bristol-Myers Squibb Co
Hua Medicine Shanghai Ltd
Laboratorio Farmaceutico CT Srl
Lactocore Inc
Noema Pharma AG
Novartis AG
Park Active Molecules
Richter Gedeon Nyrt
Tempero Bio
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Drug Profiles
alloswitch-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ALX-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
arbaclofen - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-952048 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-955829 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dipraglurant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dipraglurant ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dipraglurant IR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GET-73 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HTL-0014242 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LCGM-10 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mavoglurant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NOE-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PAM-12 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize mGluR5 for Schizophrenia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize MGLUR5 for Anxiety Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize mGLUR5 for Central Nervous System Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VU-0092273 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VU-0431316 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VU-0467558 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Dormant Products
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Discontinued Products
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Product Development Milestones
Featured News & Press Releases
Sep 29, 2021: Addex Therapeutics initiates phase 2 clinical study with Dipraglurant in blepharospasm
Jun 29, 2021: Addex Therapeutics initiates pivotal phase 2b/3 study with dipraglurant for dyskinesia associated with Parkinson’s Disease
May 17, 2021: Addex’s Dipraglurant restores syptic plasticity in models of Dystonia
Mar 18, 2020: Addex Therapeutics delays start of Dipraglurant pivotal study and reporting 2019 full year audited results
Jan 17, 2019: Experimental drug improves eye gaze behavior in fragile X syndrome
Dec 13, 2018: Sosei Heptares starts new clinical development program - First subject dosed in Phase I study of HTL0014242, a selective mGlu5 negative allosteric modulator in development to treat psychiatric and neurological disorders
Oct 18, 2017: Van Leeuwenhoeck Issues Initiation of Coverage Research Report on Addex Therapeutics and Estimated ADXN Share Price of CHF 11.5 per Share
Feb 06, 2017: Addex’s Clinical Programs and Discovery Platform Highlighted in Review of Allosteric Modulators for the Treatment of Neurodegenerative Diseases
Oct 17, 2016: Addex Therapeutics to Conduct Phase IIa Proof of Concept Study of Dipraglurant in Focal Cervical Dystonia
Jun 02, 2016: Addex Dipraglurant Positive Phase 2 Data in PD-LID Published in Leading Peer Reviewed Jourl of the Movement Disorder Society
Apr 11, 2016: Addex Reports Positive Results of an mGlu5 Receptor Occupancy Study with Dipraglurant in Healthy Volunteers
Mar 15, 2016: Addex Reports Successful Completion of an mGlu5 Receptor Occupancy Study with Dipraglurant in Healthy Volunteers
Jan 11, 2016: Addex Dipraglurant Shows Highly Statistically Significant Anti-Dyskinetic Effects Following Additiol Alysis of Data from the PD-LID Phase II Proof of Concept
Jan 04, 2016: Addex’ Dipraglurant Receives Orphan Drug Desigtion from the FDA for Levodopa-Induced Dyskinesia Associated with Parkinson’s Disease
Dec 17, 2015: Addex Reports Statistically Significant Positive Interim Data for Dipraglurant in Healthy Volunteer mGlu5 Receptor Occupancy Trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indications, 2021
Number of Products under Development by Indications, 2021 (Contd..1)
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Number of Products under Investigation by Universities/Institutes, 2021
Products under Investigation by Universities/Institutes, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by Addex Therapeutics Ltd, 2021
Pipeline by Allos Pharma Inc, 2021
Pipeline by Allyx Therapeutics Inc, 2021
Pipeline by Bristol-Myers Squibb Co, 2021
Pipeline by Hua Medicine Shanghai Ltd, 2021
Pipeline by Laboratorio Farmaceutico CT Srl, 2021
Pipeline by Lactocore Inc, 2021
Pipeline by Noema Pharma AG, 2021
Pipeline by Novartis AG, 2021
Pipeline by Park Active Molecules, 2021
Pipeline by Richter Gedeon Nyrt, 2021
Pipeline by Tempero Bio, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Dormant Products, 2021 (Contd..2)
Discontinued Products, 2021
Discontinued Products, 2021 (Contd..1)